SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Korhonen Matti)
 

Sökning: WFRF:(Korhonen Matti) > The use of unlicens...

  • Salmenkari, HannePharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland (författare)

The use of unlicensed bone marrow-derived platelet lysate-expanded mesenchymal stromal cells in colitis : a pre-clinical study

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • Elsevier,2019
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-83104
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-83104URI
  • https://doi.org/10.1016/j.jcyt.2018.11.011DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies:Finnish Funding Agency for Technology & Innovation (TEKES) 3982/31/2013Juhani Aho Medical Research Foundation, Finland  Finska Läkaresällskapet  Einar och Karin Stroems Stiftelse, Finland 
  • Background: Mesenchymal stromal cells (MSCs) are a promising candidate for treatment of inflammatory disorders, but their efficacy in human inflammatory bowel diseases (IBDs) has been inconsistent. Comparing the results from various preclinical and clinical IBD studies is also challenging due to a large variation in study designs.Methods: In this comparative pre-clinical study, we compared two administration routes and investigated the safety and feasibility of both fresh and cryo-preserved platelet-lysate-expanded human bone marrow-derived MSCs without additional licensing in a dextran sodium sulfate (DSS) colitis mouse model both in the acute and regenerative phases of colitis. Body weight, macroscopic score for inflammation and colonic interleukin (IL)-1 beta and tumor necrosis factor (TNF)alpha concentrations were determined in both phases of colitis. Additionally, histopathology was assessed and Il-1 beta and Agtr1a messenger RNA (mRNA) levels and angiotensin-converting enzyme (ACE) protein levels were measured in the colon in the regenerative phase of colitis.Results: Intravenously administered MSCs exhibited modest anti-inflammatory capacity in the acute phase of colitis by reducing IL-1 beta protein levels in the inflamed colon. There were no clear improvements in mice treated with fresh or cryopreserved unlicensed MSCs according to weight monitoring results, histopathology and macroscopic score results. Pro-inflammatory ACE protein expression and shedding were reduced by cryopreserved MSCs in the colon.Conclusions: In conclusion, we observed a good safety profile for bone marrow-derived platelet lysate-expanded MSCs in a mouse pre-clinical colitis model, but the therapeutic effect of MSCs prepared without additional licensing (i.e. such as MSCs are administered in graft-versus-host disease) was modest in the chosen in vivo model system and limited to biochemical improvements in cytokines without a clear benefit in histopathology or body weight development.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Laitinen, AnitaAdvanced Cell Therapy Centre, Finnish Red Cross Blood Service, Helsinki, Finland (författare)
  • Forsgård, Richard A.,1987-Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland(Swepub:oru)rfd (författare)
  • Holappa, MerviPharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland (författare)
  • Linden, JereDepartment of Basic Veterinary Sciences, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland (författare)
  • Pasanen, LauriPharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland (författare)
  • Korhonen, MattiAdvanced Cell Therapy Centre, Finnish Red Cross Blood Service, Helsinki, Finland (författare)
  • Korpela, RiittaPharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland (författare)
  • Nystedt, JohannaAdvanced Cell Therapy Centre, Finnish Red Cross Blood Service, Helsinki, Finland (författare)
  • Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, FinlandAdvanced Cell Therapy Centre, Finnish Red Cross Blood Service, Helsinki, Finland (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Cytotherapy: Elsevier21:2, s. 175-1881465-32491477-2566

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy